Quest Diagnostics Incorporated $DGX Shares Bought by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC raised its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 61.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,603 shares of the medical research company’s stock after acquiring an additional 3,647 shares during the period. EverSource Wealth Advisors LLC’s holdings in Quest Diagnostics were worth $1,882,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in DGX. Moneta Group Investment Advisors LLC boosted its holdings in Quest Diagnostics by 3.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 1,387 shares of the medical research company’s stock valued at $241,000 after purchasing an additional 50 shares during the last quarter. HB Wealth Management LLC raised its stake in shares of Quest Diagnostics by 0.5% during the 4th quarter. HB Wealth Management LLC now owns 11,292 shares of the medical research company’s stock valued at $1,960,000 after buying an additional 58 shares during the last quarter. Ossiam lifted its holdings in shares of Quest Diagnostics by 6.1% in the 3rd quarter. Ossiam now owns 1,059 shares of the medical research company’s stock valued at $202,000 after buying an additional 61 shares during the period. Independent Advisor Alliance lifted its holdings in shares of Quest Diagnostics by 1.6% in the 4th quarter. Independent Advisor Alliance now owns 4,298 shares of the medical research company’s stock valued at $746,000 after buying an additional 66 shares during the period. Finally, Checchi Capital Advisers LLC boosted its stake in shares of Quest Diagnostics by 5.6% in the fourth quarter. Checchi Capital Advisers LLC now owns 1,326 shares of the medical research company’s stock worth $230,000 after buying an additional 70 shares during the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Price Performance

NYSE:DGX opened at $234.84 on Friday. Quest Diagnostics Incorporated has a 52 week low of $166.76 and a 52 week high of $240.13. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $25.92 billion, a PE ratio of 24.93, a price-to-earnings-growth ratio of 2.17 and a beta of 0.58. The stock’s 50-day moving average price is $206.60 and its 200-day moving average price is $199.35.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.30. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.Quest Diagnostics’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.62 EPS. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, equities analysts expect that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 22nd. Stockholders of record on Wednesday, July 8th were given a $0.86 dividend. The ex-dividend date was Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.5%. Quest Diagnostics’s payout ratio is 36.52%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Argus set a $260.00 target price on Quest Diagnostics in a report on Wednesday. Robert W. Baird boosted their price target on Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Weiss Ratings upgraded Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, July 9th. Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Mizuho raised their price objective on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Six equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $235.31.

Insider Transactions at Quest Diagnostics

In other news, SVP Karthik Kuppusamy sold 8,147 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the transaction, the senior vice president directly owned 13,510 shares of the company’s stock, valued at $2,702,000. This represents a 37.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the completion of the sale, the senior vice president directly owned 10,335 shares in the company, valued at $2,430,585.30. This represents a 13.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,747 shares of company stock valued at $3,947,088 in the last three months. 0.88% of the stock is currently owned by company insiders.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.